Pharnext SAS - Product Pipeline Review - 2013


Naperville, IL -- (SBWIRE) -- 01/27/2014 -- Reportstack, provider of premium market research reports announces the addition of Pharnext SAS - Product Pipeline Review - 2013 market report to its offering
Pharnext SAS - Product Pipeline Review - 2013


Global Market Directs pharmaceuticals report, Pharnext SAS - Product Pipeline Review - 2013 provides data on the Pharnext SASs research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from proprietary databases, Pharnext SASs corporate website, SEC filings, investor presentations and featured press releases, both from Pharnext SAS and industry-specific third party sources, put together by team.


- Pharnext SAS - Brief Pharnext SAS overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pharnext SAS human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Pharnext SAS with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Pharnext SASs pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Pharnext SASs strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Pharnext SAS in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Pharnext SASs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Pharnext SAS.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Pharnext SAS and identify potential opportunities in those areas.

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604